Nasdaq · Healthcare
Profound Medical Corp. (PROF)
As-reported financials and recent SEC filings for Profound Medical Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$16.1M
Net income
$-42.6M
Net margin
—
Diluted EPS
$1.41
ROE
-64.1%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M | — | — |
| Gross profit | $11.4M | $7.0M | $4.3M | — | — |
| Operating income | $-41.3M | $-33.1M | $-28.7M | — | — |
| Net income | $-42.6M | $-27.8M | $-28.3M | — | — |
| Diluted EPS | $1.41 | $1.12 | $1.34 | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
EFFECT2026-05-19
View on EDGAR →8-K2026-05-15
View on EDGAR →CORRESP2026-05-15
View on EDGAR →UPLOAD2026-05-15
View on EDGAR →8-K2026-05-14
View on EDGAR →S-32026-05-12
View on EDGAR →8-K2026-05-07
View on EDGAR →10-Q2026-05-07
View on EDGAR →Largest Healthcare peers
Go deeper on PROF
Search Profound Medical Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.